Show simple item record

Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets

dc.contributor.authorCustodia, Antía
dc.contributor.authorAramburu-Núñez, Marta
dc.contributor.authorCorrea-Paz, Clara
dc.contributor.authorPosado-Fernández, Adrián
dc.contributor.authorGómez Larrauri, Ana
dc.contributor.authorCastillo, José
dc.contributor.authorGómez Muñoz, Antonio
dc.contributor.authorSobrino, Tomás
dc.contributor.authorOuro Villasante, Alberto
dc.date.accessioned2021-08-02T08:31:12Z
dc.date.available2021-08-02T08:31:12Z
dc.date.issued2021-06-25
dc.identifier.citationBiomolecules 11(7) : (2021) // Article ID 945es_ES
dc.identifier.issn2218-273X
dc.identifier.urihttp://hdl.handle.net/10810/52619
dc.description.abstractCeramide is a bioactive sphingolipid involved in numerous cellular processes. In addition to being the precursor of complex sphingolipids, ceramides can act as second messengers, especially when they are generated at the plasma membrane of cells. Its metabolic dysfunction may lead to or be a consequence of an underlying disease. Recent reports on transcriptomics and electrospray ionization mass spectrometry analysis have demonstrated the variation of specific levels of sphingolipids and enzymes involved in their metabolism in different neurodegenerative diseases. In the present review, we highlight the most relevant discoveries related to ceramide and neurodegeneration, with a special focus on Parkinson’s disease.es_ES
dc.description.sponsorshipThis study was partially supported by grants from the Xunta de Galicia (Consellería de Economía e Industria: IN607A2018/3 & IN607D 2020/09), and Science Ministry of Spain (RTI2018-102165-B-I00 & RTC2019-007373-1). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018_ NEUROATLANTIC project), INTERREG V A España Portugal (POCTEP) (0624_2IQBIONEURO_6_E) and the European Regional Development Fund (ERDF). Work in AGM lab is supported by grant IT-1106-16 from “Departamento de Educación, Universidades e Investigación” (Gobierno Vasco, Gasteiz-Virtoria, Spain). Moreover, M. Aramburu-Núñez (IFI18/00008) is recipient of iPFIS contract, and Sobrino (CPII17/00027) is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/RTI2018-102165-B-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/RTC2019-007373-1es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectceramidees_ES
dc.subjectsphingolipidses_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectneurodegenerationes_ES
dc.subjectsphingomyelinasees_ES
dc.subjectceramide synthasees_ES
dc.subjectβ-GCasees_ES
dc.subjectsphingolipidomicses_ES
dc.titleCeramide Metabolism and Parkinson’s Disease—Therapeutic Targetses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-07-23T13:27:10Z
dc.rights.holder2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2218-273X/11/7/945/htmes_ES
dc.identifier.doi10.3390/biom11070945
dc.departamentoesBioquímica y biología molecular
dc.departamentoeuBiokimika eta biologia molekularra


Files in this item

Thumbnail
Name:
biomolecules-11-00945-v2.pdf
Size:
1.597Mb
Format:
PDF
Description:
Artículo principal
View/Open

This item appears in the following Collection(s)

Show simple item record

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).